GlassScriptPhysician profile
Eden D Brandon
NPI 1063605814
$4,860.94
in general payments reported to CMS, 2019-2025
25 companies · $954 in 2025
The $954 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $177 · 2021: $785 · 2022: $842 · 2023: $907 · 2024: $877 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,701 · Education: $36.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.43 |
| Education | $36.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $877.14 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $772.59 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $545.83 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $500.24 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $483.75 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $272.06 | 2021-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $244.87 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $198.28 | 2020-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $134.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $110.74 | 2021-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $102.06 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.98 | 2019-2024 | Xifaxan |
| Pfizer INC. | $95.27 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $79.73 | 2021 | |
| Vifor Pharma, INC. | $52.94 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $41.99 | 2023-2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $39.44 | 2023-2025 | Gvoke Hypopen |
| Tactile Systems Technology INC | $37.77 | 2019 | |
| Sunovion Pharmaceuticals INC. | $36.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.28 | 2019 | |
| Abbott Laboratories | $23.89 | 2025 | Cardiomems |
| Esperion Therapeutics, INC. | $22.97 | 2021 | |
| Edwards Lifesciences Corporation | $22.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2022 | |
| Amarin Pharma, INC. | $21.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eden Brandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.